SOPHiA GENETICS (NASDAQ:SOPH) Posts Quarterly Earnings Results, Misses Expectations By $0.10 EPS

SOPHiA GENETICS (NASDAQ:SOPH) released its quarterly earnings data on Tuesday. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.10), Zacks reports. SOPHiA GENETICS had a negative return on equity of 34.95% and a negative net margin of 41.13%.The business had revenue of $19.46 million during the quarter, compared to analyst estimates of $18.13 million. SOPHiA GENETICS updated its FY 2025 guidance to EPS.

SOPHiA GENETICS Stock Performance

Shares of SOPHiA GENETICS stock traded up $0.12 during trading hours on Thursday, reaching $4.64. The company’s stock had a trading volume of 33,051 shares, compared to its average volume of 81,976. The company’s 50 day simple moving average is $3.97 and its 200 day simple moving average is $3.45. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.21 and a current ratio of 3.39. SOPHiA GENETICS has a one year low of $2.58 and a one year high of $5.30. The stock has a market cap of $313.23 million, a P/E ratio of -10.08 and a beta of 1.10.

Analysts Set New Price Targets

A number of research firms recently weighed in on SOPH. Wall Street Zen raised shares of SOPHiA GENETICS to a “hold” rating in a report on Saturday, November 1st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $8.00.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Akre Capital Management LLC lifted its position in SOPHiA GENETICS by 66.2% in the 2nd quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock valued at $11,529,000 after purchasing an additional 1,481,636 shares during the last quarter. Federated Hermes Inc. lifted its position in SOPHiA GENETICS by 16.4% in the 2nd quarter. Federated Hermes Inc. now owns 220,000 shares of the company’s stock valued at $682,000 after purchasing an additional 31,000 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in SOPHiA GENETICS by 246.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock valued at $25,341,000 after purchasing an additional 5,432,871 shares during the last quarter. 31.59% of the stock is currently owned by institutional investors.

About SOPHiA GENETICS

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.